Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | METAP2 | P50579 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28143697 | 0.82 | ALDH1A1 (0.65) | KMT2AALDH1A1HPGDHTTMAPT | |
| SCHEMBL2286441 | 0.81 | ALDH1A1 (0.58) | KMT2AALDH1A1HPGDHTTGAA | |
| SCHEMBL2775341 | 0.79 | LMNA (0.51) | KMT2AGAASMN1; SMN2RAB9AMEN1 | |
| SCHEMBL6883987 | 0.79 | LMNA (0.51) | GAASMN1; SMN2RAB9APOLB | |
| SCHEMBL5445011 | 0.79 | RAB9A (0.53) | KMT2AALDH1A1HTTHSD17B10GAA | |
| SCHEMBL12368122 | 0.79 | KMT2A (0.79) | KMT2AMETAP2TSHRHSD17B10GAA | |
| SCHEMBL16491920 | 0.78 | RAB9A (0.54) | KMT2AMETAP2ALDH1A1HTTGAA | |
| SCHEMBL16491930 | 0.78 | RAB9A (0.54) | KMT2AALDH1A1GAAMAPTMAPK1 | |
| SCHEMBL6951987 | 0.78 | CTSD (0.62) | GAASMN1; SMN2RAB9A | |
| SCHEMBL14621976 | 0.78 | CTSD (0.53) | KMT2AALDH1A1HPGDHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2278962-B1 | METHODS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-12 | — | — | EP | disclosed |
| EP-2278962-B1 | METHODS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-12 | — | — | EP | disclosed |
| US-8536226-B2 | Methods for the treatment of dermatological disorders | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-8536226-B2 | Methods for the treatment of dermatological disorders | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-8536226-B2 | Methods for the treatment of dermatological disorders | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-20120283330-A1 | METHODS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-11-08 | — | — | US | disclosed |
| US-20120283330-A1 | METHODS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-11-08 | — | — | US | disclosed |
| US-20120283330-A1 | METHODS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-11-08 | — | — | US | disclosed |
| US-8247453-B2 | Methods for the treatment of dermatological disorders | JANSSEN PHARMACEUTICA, NV (BE) | 2012-08-21 | — | — | US | disclosed |
| US-8247453-B2 | Methods for the treatment of dermatological disorders | JANSSEN PHARMACEUTICA, NV (BE) | 2012-08-21 | — | — | US | disclosed |
| US-8247453-B2 | Methods for the treatment of dermatological disorders | JANSSEN PHARMACEUTICA, NV (BE) | 2012-08-21 | — | — | US | disclosed |
| US-20090215902-A1 | METHODS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA, NV (BE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215902-A1 | METHODS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA, NV (BE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215902-A1 | METHODS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA, NV (BE) | 2009-08-27 | — | — | US | disclosed |
| WO-2009105647-A1 | METHODS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215902-A1 | METHODS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | MC5R, MC1R, MC2R | KMT2A 2727/4885METAP2 426/4885ALDH1A1 887/4885 |
| US-20120283330-A1 | METHODS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | MC5R, MC1R, MC2R | KMT2A 2727/4885METAP2 426/4885ALDH1A1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.